Mesoblast Limited Files for Proposed Issue and Quotation of Securities on ASX

On April 8, 2026, Mesoblast Limited filed a Form 6-K with the SEC, reporting recent activities involving the issuance and quotation of securities on the Australian Securities Exchange (ASX). The filing incorporates two primary exhibits: Appendix 3B, filed on April 7, 2026, which serves as a new issue announcement and a notification of a proposed issue of securities; and Appendix 2A, filed on April 8, 2026, which is an application for the quotation of these securities. These filings indicate that Mesoblast is proceeding with an equity-related transaction to increase its share capital. As a foreign private issuer, Mesoblast provides these updates to ensure compliance with both Australian regulatory requirements and U.S. reporting standards. The documents do not specify the exact number of securities or the intended use of proceeds within the summary text of the 6-K, but they confirm the formal administrative steps for the issuance and listing of new shares on the ASX.